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Introduction
In patients with hemophilia, the residual plasma level of clotting factor (either factor [F] VIII or FIX) is considered to be the most critical predictor of spontaneous bleeding [1] . It is on this basis that hemophilia patients are phenotypically classified into severe, moderate and mild categories. Several observations suggest that this classification may be inadequate in the management of hemophilia patients [2] . For instance, 10-20% of patients with severe hemophilia A have minimal or no bleeding complications during adulthood [3, 4] . Furthermore, there is a paucity of data showing a strong correlation between FVIII level and bleeding symptoms in patients with moderate or mild hemophilia A. In spite of this knowledge gap, hemophilia treatment strategies continue to be formulated and often implemented, sometimes pre-emptively, based on residual factor level (i.e. prophylaxis vs. on-demand therapies in patients with severe hemophilia).
Appreciation of the real prognostic value of residual factor level is, therefore, a primary, clinically relevant unmet need. This could be achieved, however, only by an a priori definition of what constitutes 'clinically severe hemophilia' (CSH), irrespective of the residual factor level. To this aim, any effort should be based on a twostage process: a priori definition of a consensus statement for CSH and its subsequent validation. In this manuscript, we report on the development and validation of criteria to define CSH.
Methods

Development of consensus criteria for CSH
Hemophilia Center Directors with experience in the diagnosis and treatment of hemophilia and caring for at least 100 hemophilia patients were invited to participate in a consensus panel during the ISTH-SSC meeting that was held in Amsterdam in 2013. Subsequent engagement of panelists was conducted using the Delphi approach distributed through the REDCAP survey system [5, 6] . Delphi consensus was achieved through a number of iterations. In each iteration, participants were asked to score a number of statements related to the definition of CSH on a 9-point scale ranging from strongly disagree to strongly agree and divided into three score tiers (1-3, 4-6 and 7-9 points). Table S1 includes the list of questions submitted for the Delphi rounds. The inter-panelist agreement was considered reached when ≥ 80% of answers belonged to the same score tier. When the agreement was not reached, the questions were subjected to the next question iteration. Questions in which 50% of panelists reached consensus were then carried to the next round, and the rest were then discarded. Delphi rounds were concluded when the consensus was finally reached for all initially proposed questions.
Validation of the consensus criteria
As a second step, we validated the developed consensus criteria. The validation was initiated during the ISTH-SSC meeting held in Toronto in 2015, in which a broader group of Hemophilia Treatment Centers (HTC) were invited to provide anonymous clinical data regarding consensus criteria and residual FVIII/FIX levels, as recorded from clinical charts at diagnosis. We aimed to demonstrate that residual FVIII/FIX levels had a sufficient predictive ability (defined by a c-statistic > 0.85) for a severe bleeding phenotype. Each participating HTC was asked to enroll at least 20 consecutive hemophilia A or B patients irrespective of their laboratory phenotype, born between 1 January 1990 and 31 December 2010. To minimize selection bias, physicians were asked to enroll at least 20 consecutive patients seen at the clinic in a definite time frame that was left to the physician's discretion and having a complete follow-up of the first 3 years of life in their medical files. Patients who started prophylaxis prior to any bleeding episodes were not eligible. Prophylaxis was defined as long-term, regular treatment with at least one infusion per week for a minimum of 46 weeks per year. Patients who developed inhibitors were considered eligible. Institutional Review Board approval was obtained by each HTC when required, according to the policy of the participants' country/institution. Residual FVIII/FIX levels at diagnosis were mandatory for the validation step. They were assessed by each local laboratory by one-stage clotting assay.
Statistics and sample size for the validation study Differences among subgroups: we assessed the sensitivity and specificity of the residual factor (FVIII and FIX) in the prediction of a CSH phenotype using area under the receiver operating characteristic curve (ROC AUC). As mentioned above, we arbitrarily considered a c-statistic for FVIII/FIX > 0.85 as a satisfactory predictive power endpoint. For this purpose, at least 75 patients with severe hemophilia A or B and 75 patients with non-severe hemophilia would be required to demonstrate that the lower 95% confidence interval (CI) of the ROC AUC is above 0.90 [7] [8] [9] . Because we anticipated a 1:2 ratio between severe and non-severe hemophiliacs, 75 severe and 150 nonsevere patients were considered sufficient to complete the validation study. Data were analyzed using R package pROC (R Development Core Team. R: A language and environment for statistical computing (v 3.3.2); R Foundation for Statistical Computing, Vienna, Austria).
Results
Development of consensus criteria
Seventeen HTC Directors met the inclusion criteria and agreed to participate in the initial Delphi rounds and answered questions. After two Delphi rounds, consensus was reached on the bleeding symptoms that are associated with a clinically severe hemophilia phenotype: namely, first spontaneous bleeding before age 6 months, spontaneous joint bleeding before age 2 years, unprovoked intracranial hemorrhage, spontaneous subcutaneous hematomas (at least one palm-sized or > 3 coin-sized) and at least 10 bleeding events/ year if treated on demand. In a third round we asked them to score the relative importance of the five symptoms, and in a fourth round we requested HTC Directors to provide a cutoff for a summative score of each symptom weight. Final consensus criteria are reported in Table S2 .
Validation of consensus criteria: patients' analyses
In the second phase, data from 19 participating HTC were analyzed, totaling 421 hemophilia patients. All participating centers are listed in the Appendix. The median CSH score in the study population was 2 (interquartile range [IQR], 0-5). The clinical data for these patients, distinguished according to the CSH score results, are reported in Table S3 .
Patients who developed an inhibitor before the age of 3 years (n = 66) had a higher severity score than those who did not develop an inhibitor (n = 355) (median score 3 and 2, IQR 1-5 and 0-4, respectively; P < 0.0001). The majority of those who developed inhibitors before the age of 3 years (56, 85%) had a residual FVIII/FIX level < 1 IU dL
À1
. Similarly, patients who started prophylaxis before the age of 3 years (n = 133) had a higher severity score than those who started prophylaxis later (n = 273) (median score 3 and 1, IQR 1-4 and 0-5, respectively; P = 0.001). The majority of those who began prophylaxis before the age of 3 years (133, 91%) had a residual FVIII/FIX level < 1 IU dL À1 . Figure 1 shows the distribution of residual FVIII and FIX levels in patients with hemophilia A and hemophilia B distinguished by level of the proposed severity score. Figure S1 shows the ability of residual FVIII/FIX, as measured at diagnosis by one-stage clotting assay, to discriminate a severe clinical phenotype, according to the a priori definition of a score ≥ 3. The sensitivity was 0.87 (95% CI, 0.81-0.91) for FVIII and 0.68 (95% CI, 0.43-0.87) for FIX when considering the usual cut-off of 1 IU/dL; the specificity was 0.52 (95% CI, 0.44-0.60) and 0.65 (95% CI, 0.50-0.78) for FVIII and FIX, respectively. Figure 2 shows the FVIII and FIX receiver operator curves for the discrimination of severe phenotype. The c-statistic for the area under the curves was comparable for both hemophilia A and hemophilia B patients (0.76 and 0.71, respectively; P = 0.44).
Discussion and conclusions
Our results demonstrate that the residual FVIII/FIX activity level accounts for around 70% of the bleeding phenotype and the remaining 30% are potentially related to other unexplained individual variables. The main limitations of our study are the retrospective design and the lack of centralized laboratory measurement of residual FVIII/FIX [10] . Moreover, the early implementation of prophylaxis reduces the observation period of the natural history of the disease, especially in those with a severe and moderately severe form of the disease.
However, the sample size renders our data robust enough to show that residual factor levels below 1 IU dL À1 identify 87% of clinically severe hemophilia A patients but only 68% of clinically severe hemophilia B patients as defined by means of the proposed CHS score. This suggests the need for further prognostic improvement. It should be noted that the higher proportion of patients with hemophilia A among those with a severity score above 3 also confirms in this cohort of patients the possibility of a milder bleeding phenotype in patients with hemophilia B, as previously reported [11] [12] [13] . Another critical issue is the poor specificity of reduced residual factor level, which may suggest the need for starting prophylaxis even if there is a minority of patients with residual factor < 1 IU dL À1 who will not develop a clinically severe phenotype, at least in the first 3 years. For example, for hemophilia A the 1 IU dL À1 cut-off has 92% sensitivity and 48% specificity (0.52 in the plot, being represented as 1-specificity) for detecting a severe phenotype; for hemophilia B, the sensitivity is 89% and specificity 52% for the same cut-off. 
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Additional supporting information may be found online in the Supporting Information section at the end of the article: Fig. S1 . Correlation between clinical severity score and residual factor level at diagnosis in hemophilia patients not receiving prophylaxis. Horizontal and vertical lines are drawn at a residual factor level of 1 IU dL À1 (corresponding to the laboratory-based 'severe' definition) and at a severity score ≥ 3. Considering the clinical severity score as the reference standard, the intersection of the two lines clockwise defines four areas: true negatives (TN), false negatives (FN), true positives (TP) and false positives (FP). Table S1 . Full set of questions asked in the first Delphi round. Table S2 . Symptoms that define a severe bleeding phenotype in a patient with hemophilia and relative score assigned after four Delphi rounds. Table S3 . Clinical characteristics of the 421 patients enrolled in the validation step distinguished on the basis of the 'clinically severe hemophilia' (CSH) score.
